February 2015

**Racecadotril (Hidrasec®▼)** for symptomatic treatment of acute diarrhoea in infants, children and adults

The New Therapies Subgroup discussed the above drug at its meeting on the 18th December 2012. The recommendation of this subgroup is as follows:* 

The New Therapies Subgroup of the GMMMG considered the use of racecadotril for acute diarrhea in infants, children and adults.  

The group does not recommend the use of racecadotril for acute diarrhea in infants, children and adults.  
There is no robust data to support the use of racecadotril for this indication over existing therapies. 

According to set criteria racecadotril was deemed to be low priority for funding.

Review date: February 2018

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.  
▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.